Precision Medicine in Oncology® | Specialty

Genetic Analysis Identifies New Targets in Triple-Negative Breast Cancer

December 6th 2012

Patients with triple-negative breast cancer who have residual disease after receiving neoadjuvant chemotherapy have a series of genetic alterations that are clinically targetable and may warrant further study.

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

December 5th 2012

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

December 5th 2012

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.

EGFR Mutation Status Might Predict Sorafenib Benefit in NSCLC

November 30th 2012

Results of the phase III MISSION trial showed that third- or fourth-line treatment with sorafenib did not improve overall survival in patients with advanced non–small cell lung cancer.

Taking a Look at Four Noteworthy Studies

November 28th 2012

The pace of discovery in breast cancer research has been brisk in the past year, leading not only to the approval of several new therapies but also to clinical trial results with the potential to change practice.

Peering Deeper Into the Black Box

November 28th 2012

Over the past decade, there has been an explosion of knowledge regarding the fundamental drivers of the malignant phenotype.

Dr. Weitzel on Combination Therapies in Breast Cancer

November 26th 2012

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment

November 19th 2012

Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.

Molecular and Personalized Medicine in Breast Cancer

November 15th 2012

Managing Skeletal-Related Events in Breast Cancer, Part II

November 15th 2012

Managing Skeletal-Related Events in Breast Cancer, Part I

November 15th 2012

Emerging Therapies in Metastatic Breast Cancer

November 15th 2012

Chemotherapy in Advanced Breast Cancer

November 15th 2012

Management of Metastatic Breast Cancer, Part II

November 15th 2012

Improving the Management of Metastatic Breast Cancer, Part I

November 15th 2012

NewYork-Presbyterian/Columbia & Cornell Cancer Program: Collaborating for Advances in Research and Patient Care

November 13th 2012

In September 2012 the new joint Cancer Center at Weill Cornell Medical College and NewYork-Presbyterian Hospital was established, bringing together basic, translational, and clinical researchers to operate within a vast, collaborative infrastructure.

In Breast Cancer, Targeted Agents Boost Hormonal Therapies

November 12th 2012

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

How Payers and Oncologists Really Feel About Clinical Pathways

November 6th 2012

Stakeholders weigh in on evidence-based pathway approach designed to decrease practice variation, improve outcomes, and reduce cost.

Dr. Sekulic on Vismodegib for Basal-Cell Nevus Syndrome

November 6th 2012

Aleksandar Sekulic, MD, PhD, from the Mayo Clinic, Scottsdale, AZ, discusses the administration of vismodegib for the treatment and prevention of basal-cell carcinoma in patients with basal-cell nevus syndrome.

Overcoming Genetic Transformation in Multiple Myeloma

November 6th 2012

The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, which is best achieved by targeted combination therapy very early in the course of disease.